What should I know about testosterone and the heart — the one-paragraph clinical summary?

Testosterone and cardiovascular health have a complex, bidirectional relationship: low testosterone is associated with higher cardiovascular mortality (observational data), TRT in hypogonadal men does not increase heart attack or stroke risk (TRAVERSE RCT), but TRT does increase atrial fibrillation risk by 16% and PE risk 2.3-fold (TRAVERSE), making TRT a therapy requiring cardiovascular pre-screening (ECG, blood pressure, hematocrit, AF risk assessment) by a qualified physician, ongoing monitoring every 3–6 months including hematocrit and blood pressure, and individual risk stratification rather than population-wide prescription or telehealth dispensing without evaluation (Lincoff et al., NEJM, 2023).

This one paragraph is the clinically complete summary. It acknowledges the benefits (treating real hypogonadism reduces morbidity), the safety signals (AF and PE are real, dose-dependent risks), and the clinical process (evaluation and monitoring). Men deserve this information upfront, not in the fine print after they have already started therapy.

Honesty Scale: Solid (1) for this synthesis based on the TRAVERSE data and pre-existing evidence.

What to do: Share this summary with your prescribing physician if you are pursuing TRT, and ask whether each of the pre-screening and monitoring elements has been addressed in your care plan.

For the full picture, read The Testosterone/TRT Deep Dive

## Category 15: Blood Pressure (incl. Masked Hypertension)